After a 27% Plunge, Is Halozyme a Bad News Buy?

Halozyme Therapeutics, Inc.'s stock plummeted by 27% on Friday after management reported that it had halted enrollment and dosing in its phase 2 pancreatic cancer trial of PEGPH20 as a "precautionary measure." The trial was halted at the request of an independent Data Monitoring Committee, or DMC, based on a possible observed difference in thromboembolic (blood clot) events among study participants in the PEGPH20 arm.

Halozyme's management has not released additional information as of this writing, with CEO Dr. Helen Torley merely noting that "We will be providing additional information to the DMC as quickly as possible so they can complete their assessment and we can determine next steps."

In this segment of Friday's market checkup, Motley Fool health care analysts David Williamson and Michael Douglass discuss Halozyme's halted enrollment, the company's overall position, and whether this is a good opportunity to invest in the stock.

Looking for the next great investment opportunity?
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 06, 2014, at 12:35 PM, baloneyspotter wrote:

    Wow, another pathetic analysis (with all due respect) - this is not the main future revenue driver for the next year to 2. Have you looked at what the analysts have said about that, "only a few bucks on the price" - and they have now several drugs w/ Roche on the market which could bring in many millions in royalty very soon. They add a substance to intravenous drugs allowing them to be given subQ, saving much time to get into the blood stream. So, per this writer, do not invest in any biotech names, even if the bad news is on early development and they have a diverse pipeline. In fact, per this writer, if they spend more than $10 million per year, that must be too much?...lol.

  • Report this Comment On April 06, 2014, at 4:55 PM, derkman wrote:

    Sad analysis from these fools. How can a person make so many mistakes and still call themselves a fool? Go back and do some research that is newer than last year and then tell us why this halt in the study isn't very important to HALO. You can thank me later.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2904289, ~/Articles/ArticleHandler.aspx, 10/21/2014 8:10:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement